Skip to main content
Journal cover image

A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.

Publication ,  Journal Article
Hess, CN; Al-Khatib, SM; Granger, CB; Lopes, R
Published in: Expert Rev Cardiovasc Ther
September 2013

Atrial fibrillation (AF) is associated with significant mortality and morbidity, and stroke represents the most-feared complication. Consequently, AF treatment has focused on thromboprophylaxis, with warfarin as the mainstay of therapy. However, concerns over ease of use and safety have limited its use. Three novel oral anticoagulants have been approved for use in stroke prevention in AF based on randomized data: 1) dabigatran, studied in Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY); 2) rivaroxaban, studied in Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF); and 3) apixaban, studied in Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). In this review, we focus on apixaban and discuss subgroup analyses that have been performed in the three trials comparing novel oral anticoagulants with warfarin. We conclude with recommendations regarding further investigations.

Duke Scholars

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

September 2013

Volume

11

Issue

9

Start / End Page

1105 / 1114

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Pyridones
  • Pyrazoles
  • Humans
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hess, C. N., Al-Khatib, S. M., Granger, C. B., & Lopes, R. (2013). A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Rev Cardiovasc Ther, 11(9), 1105–1114. https://doi.org/10.1586/14779072.2013.824181
Hess, Connie N., Sana M. Al-Khatib, Christopher B. Granger, and Renato Lopes. “A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.Expert Rev Cardiovasc Ther 11, no. 9 (September 2013): 1105–14. https://doi.org/10.1586/14779072.2013.824181.
Hess CN, Al-Khatib SM, Granger CB, Lopes R. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105–14.
Hess, Connie N., et al. “A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.Expert Rev Cardiovasc Ther, vol. 11, no. 9, Sept. 2013, pp. 1105–14. Pubmed, doi:10.1586/14779072.2013.824181.
Hess CN, Al-Khatib SM, Granger CB, Lopes R. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105–1114.
Journal cover image

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

September 2013

Volume

11

Issue

9

Start / End Page

1105 / 1114

Location

England

Related Subject Headings

  • Treatment Outcome
  • Stroke
  • Pyridones
  • Pyrazoles
  • Humans
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anticoagulants
  • 3201 Cardiovascular medicine and haematology